tracken
PureTech Health Plc - ADR Aktie News
Neutral
Business Wire
●
etwa 4 Stunden alt
BOSTON--(BUSINESS WIRE)--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis.
Neutral
Business Wire
●
3 Tage alt
BOSTON--(BUSINESS WIRE)--PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data for LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia.
Neutral
Business Wire
●
etwa 2 Monate alt
BOSTON--(BUSINESS WIRE)--PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with IPF.
Neutral
Business Wire
●
2 Monate alt
BOSTON--(BUSINESS WIRE)--PureTech Presents New Data from Deupirfenidone Phase 2b Open-Label Extension, Further Supporting Potential to Serve as New Standard of Care in IPF.
Neutral
Seeking Alpha
●
3 Monate alt
PureTech Health plc (NASDAQ:PRTC ) Q2 2025 Earnings Call August 28, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior VP of Communications & Head of Investor Relations Eric Elenko - Co-Founder & President Luba Greenwood - Corporate Participant Robert Lyne - Interim Chief Executive Officer Sven Dethlefs - Corporate Participant Conference Call Participants Heidi Danielle Jacobson ...
Neutral
Business Wire
●
3 Monate alt
BOSTON--(BUSINESS WIRE)--PureTech today announces its half-yearly results for the six months ended June 30, 2025.
Neutral
Business Wire
●
4 Monate alt
BOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit.
Neutral
Business Wire
●
4 Monate alt
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
